Terns Pharmaceuticals Stock Performance
| TERN Stock | USD 5.64 0.04 0.71% |
Terns Pharmaceuticals holds a performance score of 22 on a scale of zero to a hundred. The entity has a beta of 0.43, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Terns Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Terns Pharmaceuticals is expected to be smaller as well. Use Terns Pharmaceuticals potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Terns Pharmaceuticals.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Terns Pharmaceuticals are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Terns Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.71 | Five Day Return 15.57 | Year To Date Return (0.53) | Ten Year Return (69.33) | All Time Return (69.33) |
Last Split Factor 1000:50 | Last Split Date 2013-11-04 |
1 | Terns Pharma Price Target Lowered by BMO Capital TERN Stock News | 05/13/2025 |
2 | Acquisition by Gordon Carl L of 4676 shares of Terns Pharmaceuticals at 6.85 subject to Rule 16b-3 | 05/16/2025 |
3 | Acquisition by Burroughs Amy L. of 1250000 shares of Terns Pharmaceuticals at 7.31 subject to Rule 16b-3 | 06/03/2025 |
4 | Tern Announces Earnings Results | 06/05/2025 |
5 | Acquisition by Fellows David A of 45000 shares of Terns Pharmaceuticals at 4.1 subject to Rule 16b-3 | 06/11/2025 |
6 | Acquisition by Andrew Gengos of 5000 shares of Terns Pharmaceuticals at 3.75 subject to Rule 16b-3 | 06/13/2025 |
7 | Navigation Pioneer Stan Honey Joins TERN to Advance AI-Powered GPS Alternative | 06/17/2025 |
8 | Acquisition by Burroughs Amy L. of 23314 shares of Terns Pharmaceuticals at 3.8702 subject to Rule 16b-3 | 06/25/2025 |
9 | Amy L. Burroughs Acquires 23,314 Shares of Terns Pharmaceuticals, Inc. Stock | 06/27/2025 |
10 | Insider Buying Andrew Gengos Acquires Additional Shares of Terns Pharmaceuticals Inc | 07/01/2025 |
11 | Terns Pharmaceuticals CEO Director Acquires 98 percent More Stock - | 07/08/2025 |
12 | Terns Pharmaceuticals A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts - Seeking Alpha | 07/11/2025 |
13 | Disposition of 623 shares by Orbimed Advisors Llc of Terns Pharmaceuticals at 10.0 subject to Rule 16b-3 | 07/16/2025 |
| Begin Period Cash Flow | 79.9 M | |
| Total Cashflows From Investing Activities | -12.4 M |
Terns Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 271.00 in Terns Pharmaceuticals on April 21, 2025 and sell it today you would earn a total of 293.00 from holding Terns Pharmaceuticals or generate 108.12% return on investment over 90 days. Terns Pharmaceuticals is currently generating 1.2671% in daily expected returns and assumes 4.4798% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Terns, and 75% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Terns Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Terns Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Terns Pharmaceuticals, and traders can use it to determine the average amount a Terns Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2829
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TERN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.48 actual daily | 40 60% of assets are more volatile |
Expected Return
| 1.27 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 22 78% of assets perform better |
Based on monthly moving average Terns Pharmaceuticals is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Terns Pharmaceuticals by adding it to a well-diversified portfolio.
Terns Pharmaceuticals Fundamentals Growth
Terns Stock prices reflect investors' perceptions of the future prospects and financial health of Terns Pharmaceuticals, and Terns Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Terns Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 159.56 M | ||||
| Shares Outstanding | 87.34 M | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (87.7 M) | ||||
| Net Income | (88.85 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 1.35 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (70.02 M) | ||||
| Earnings Per Share | (1.08) X | ||||
| Market Capitalization | 492.59 M | ||||
| Total Asset | 363.93 M | ||||
| Retained Earnings | (421.48 M) | ||||
| Working Capital | 346.46 M | ||||
About Terns Pharmaceuticals Performance
By examining Terns Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Terns Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Terns Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.5 K | 2.2 K | |
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.27) |
Things to note about Terns Pharmaceuticals performance evaluation
Checking the ongoing alerts about Terns Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Terns Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Terns Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51. | |
| Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimers Disease |
- Analyzing Terns Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Terns Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Terns Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Terns Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Terns Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Terns Pharmaceuticals' stock. These opinions can provide insight into Terns Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.